Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 10-2020 | 07-2020 | 04-2020 | 01-2020 | 10-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,428 | 4,235 | 4,989 | 2,094 | 1,650 |
| Receivables | 166 | 180 | 196 | 172 | 199 |
| Other current assets | 2,646 | 155 | 126 | 0 | 0 |
| TOTAL | $4,408 | $4,660 | $5,453 | $2,524 | $2,199 |
| Non-Current Assets | |||||
| PPE Net | 170 | 246 | 108 | 215 | 236 |
| TOTAL | $170 | $246 | $108 | $215 | $236 |
| Total Assets | $4,578 | $4,906 | $5,561 | $2,739 | $2,435 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,685 | 1,416 | 1,090 | 1,094 | 1,510 |
| Accrued Expenses | 198 | 301 | 471 | 473 | 196 |
| Other current liabilities | N/A | 49 | 66 | N/A | N/A |
| TOTAL | $1,982 | $1,925 | $1,627 | $1,651 | $1,769 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 0 | 0 | 84 | 63 |
| Other Non-Current Liabilities | 0 | -587 | 854 | -973 | -621 |
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,982 | $1,925 | $1,627 | $1,651 | $1,769 |
| Shareholders' Equity | |||||
| Common Shares | 137,257 | 137,257 | 137,257 | 134,381 | 132,984 |
| Retained earnings | -180,738 | -180,516 | -178,427 | -175,938 | -173,707 |
| Other shareholders' equity | 18,936 | 20,113 | 20,013 | 18,137 | 17,453 |
| TOTAL | $2,596 | $2,394 | $4,788 | $115 | $45 |
| Total Liabilities And Equity | $4,578 | $4,319 | $6,415 | $1,766 | $1,814 |